Revvity, Inc. (NYSE:RVTY) Shares Sold by First National Bank of Omaha

First National Bank of Omaha reduced its stake in Revvity, Inc. (NYSE:RVTY - Free Report) by 10.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 89,692 shares of the company's stock after selling 10,664 shares during the quarter. First National Bank of Omaha owned approximately 0.07% of Revvity worth $11,458,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Orion Portfolio Solutions LLC lifted its stake in shares of Revvity by 51.6% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 4,746 shares of the company's stock valued at $606,000 after buying an additional 1,616 shares in the last quarter. EdgePoint Investment Group Inc. raised its holdings in Revvity by 34.6% during the third quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock valued at $343,108,000 after acquiring an additional 690,534 shares during the period. Kovitz Investment Group Partners LLC lifted its position in shares of Revvity by 9.6% in the third quarter. Kovitz Investment Group Partners LLC now owns 9,400 shares of the company's stock valued at $1,201,000 after acquiring an additional 824 shares in the last quarter. Wahed Invest LLC boosted its stake in shares of Revvity by 11.6% in the third quarter. Wahed Invest LLC now owns 2,987 shares of the company's stock worth $382,000 after acquiring an additional 310 shares during the period. Finally, State Street Corp grew its position in shares of Revvity by 0.3% during the third quarter. State Street Corp now owns 5,180,169 shares of the company's stock worth $661,767,000 after purchasing an additional 17,832 shares in the last quarter. Institutional investors own 86.65% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RVTY shares. Sanford C. Bernstein lowered their price target on Revvity from $150.00 to $145.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. TD Cowen boosted their target price on shares of Revvity from $141.00 to $144.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Wells Fargo & Company assumed coverage on shares of Revvity in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $130.00 target price for the company. Leerink Partners increased their price objective on shares of Revvity from $130.00 to $135.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Finally, Barclays dropped their price target on Revvity from $140.00 to $135.00 and set an "overweight" rating for the company in a research note on Monday, November 25th. Seven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $131.73.

Insiders Place Their Bets

In other news, insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the transaction, the insider now owns 19,652 shares of the company's stock, valued at $2,392,237.96. The trade was a 9.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.60% of the stock is owned by company insiders.

Revvity Trading Up 1.2 %

NYSE:RVTY traded up $1.37 during mid-day trading on Friday, hitting $116.46. 709,615 shares of the stock traded hands, compared to its average volume of 921,991. Revvity, Inc. has a 52 week low of $88.90 and a 52 week high of $129.50. The firm's 50 day moving average is $118.87 and its two-hundred day moving average is $116.25. The stock has a market capitalization of $14.17 billion, a price-to-earnings ratio of 56.26, a PEG ratio of 3.57 and a beta of 1.03. The company has a quick ratio of 2.97, a current ratio of 3.56 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.15. The company had revenue of $684.10 million during the quarter, compared to analyst estimates of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. On average, equities research analysts predict that Revvity, Inc. will post 4.85 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.24%. Revvity's dividend payout ratio is currently 13.53%.

Revvity announced that its board has approved a share repurchase plan on Monday, November 4th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its stock is undervalued.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.